학술논문
Continuous enzalutamide after progression of metastatic castration-resistant prostate cancer treated with docetaxel (PRESIDE): an international, randomised, phase 3b study
Document Type
Article
Author
Source
In The Lancet Oncology November 2022 23(11):1398-1408
Subject
Language
ISSN
1470-2045